Skip to main content

FDA Approves Combo Meningitis Vaccine for Infants


June 14, 2012 — The US Food and Drug Administration (FDA) has approved a combination meningitis vaccine for infants and children aged 6 weeks through 18 months, the agency announced today.
The FDA said this is the first meningococcal vaccine that can be taken by children as young as 6 weeks of age.
The vaccine, called Menhibrix (GlaxoSmithKline Biologicals), immunizes against 2 types of bacteria: Neisseria meningitidis (serogroups C and Y) and Haemophilus influenzae type B (Hib). Each bacterium can infect the lining that surrounds the brain and spinal cord, according to the FDA.
Both meningococcal and Hib diseases can cause death or serious and permanent damage such as mental retardation and blindness. The diseases can progress rapidly, and their symptoms are hard to distinguish from those of other common childhood conditions, making them particularly dangerous for children younger than 2 years of age.
The FDA determined that Menhibrix is effective based on tests conducted with several hundred US infants and toddlers who received the vaccine. Their immune responses to the Hib component resembled those of infants and toddlers who received a vaccine against invasive Hib disease. Menhibrix also produced antibodies against the meningococcal component at levels, indicating that it would offer protection against meningococcal disease caused by serogroups C and Y of N meningitidis.
The vaccine’s safety was established by a study of roughly 7500 infants and toddlers in the United States, Mexico, and Australia. Pain, redness, and swelling at the injection site; irritability; and fever were common adverse reactions.
Menhibrix is administered in 4 doses at months 2, 4 and 6, with the fourth dose administered between months 12 and 16. The first dose can be given as early as 6 weeks, and the last as late as 18 months.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approvals: Pazopanib for Advanced Soft Tissue Sarcoma

CLINICAL CONTEXT Pazopanib was first approved by the US Food and Drug Administration (FDA) in 2009 when it became the sixth drug approved to treat advanced renal cell carcinoma. It is a small molecule with a mechanism of action as a tyrosine kinase inhibitor, specifically targeting receptors involved in angiogenesis and tumor cell proliferation. These include vascular endothelial growth-factor receptors 1, 2, and 3; platelet-derived growth-factor receptors α and β; fibroblast growth-factor receptors 1 and 3; stem cell factor receptors; interleukin-2-inducible T-cell kinase; leukocyte-specific protein tyrosine kinase; and transmembrane glycoprotein-receptor tyrosine kinase. STUDY SYNOPSIS AND PERSPECTIVE The FDA has approved pazopanib ( Votrient ) for the treatment of advanced soft tissue sarcoma in patients who have received previous chemotherapy. Pazopanib is already marketed for the treatment of advanced renal cell carcinoma; when it was approved in 2009, it became the six...
Post a Comment
Read more